Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer
Alfredo Addeo, Medical Oncologist at the Department of Oncology at the University Hospital of Geneva, shared a post on X by CA: A Cancer Journal for Clinicians, about a paper he co-authored with colleagues, published in the same journal:
“Hot off the press, a Must-read review on optimizing treatment for Lung Cancer with activating EGFR mutations, a true game changer in targeted therapy.
TKIs have transformed outcomes, but the journey continues.
Thanks to all the co-authors, great teamwork.”
Quoting CA: A Cancer Journal for Clinicians’ post:
“Activating mutations in EGFR gene have revolutionized the management of Lung Cancer, enabling the development of TKIs. New review on strategies to optimize treatment.”
Title: Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Authors: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo.
You can read the Full Article in CA: A Cancer Journal for Clinicians.
More posts featuring Alfredo Addeo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023